Tumour invasion and metastasis initiated by microRNA-10b in breast cancer

Ma, Li; Teruya‐Feldstein, Julie; Weinberg, Robert A.

doi:10.1038/nature06174

Cited by 2,328 publications

(2,186 citation statements)

References 45 publications

Supporting

Mentioning

2,069

Contrasting

Unclassified

Order By: Relevance

“…MiR-10b was first identified as a so-called 'oncomir' in breast cancer, 33 where it enhanced migration and invasion. Several other studies subsequently found increased expression of miR-10b to be associated with aggressive behavior in various cancers.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

microRNA-10b is a prognostic biomarker for melanoma

et al. 2016

View full text Add to dashboard Cite

Malignant melanoma is an aggressive form of skin cancer. Recently, drug therapy of advanced disease has been revolutionized by new agents. More therapeutic options, coupled with the desire to extend treatment to the adjuvant setting mean that prognostic biomarkers that can be assayed from formalin-fixed paraffin-embedded clinical would be valuable. microRNAs have potential to fill this need. We analyzed 377 microRNAs in 79 primary melanomas and 32 metastases using a split sample discovery strategy. From a discovery analysis using 40 thick primary melanomas (20 cases with metastasis and 20 controls without metastasis at 5 years), microRNA expression was measured by quantitative RT-PCR (QRT-PCR). MiR-10b emerged as a candidate prognostic microRNA. This was confirmed in an independent validation set of thick primary melanomas (20 cases with metastasis and 19 controls without metastasis at 5 years). In the combined discovery and validation cohorts (n = 79), miR-10b expression showed a 3.7-fold increase in expression between cases and controls (P = 0.005) and showed a trend of increasing expression between primary melanomas and their matched metastases (Po 0.001). In situ hybridization showed expression was in melanoma cells and correlated with expression measured by QRT-PCR (P = 0.0005). We used the combined discovery and validation samples to verify the prognostic value of additional candidate microRNAs identified from other studies, and proceeded to analyze miR-200b. We demonstrated that miR-10b and miR-200b showed independent prognostic value (P = 0.002 and 0.047, respectively) in multivariable analysis alongside known clinico-pathological prognostic features (eg, Breslow thickness) using a Cox proportional hazards regression model. Furthermore, the addition of these microRNAs to the clinico-pathological features led to an improved regression model with better identification of aggressive thick melanomas. Taken together, these data suggest that miR-10b is a new prognostic microRNA for melanoma and that there could be a place for microRNA analysis in stratifying melanoma for therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Furthermore, the considerably more prevalent view of miR-10b is that it is an oncomir. 33,[40][41][42][43] The mechanistic role of miR-10b in melanoma was not assessed in this study and remains to be established.…”

Section: Discussionmentioning

confidence: 99%

microRNA-10b is a prognostic biomarker for melanoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…4 Recent studies on the role of miRNA in breast cancer metastasis gave rise to the notion that miRNA may also be helpful in predicting the progression and metastasis of prostate cancer. [5][6][7][8] However, to date, few articles have investigated miRNA regulation in prostate cancer and only five studies have examined miRNA expression in more than 10 samples, with highly inconsistent results. 2,[9][10][11][12][13] Schaefer et al 4 reported that there is no overlapping subset between the down-and upregulated miRNA patterns of previous studies.…”

Section: Introductionmentioning

confidence: 99%

Do microRNA 96, 145 and 221 expressions really aid in the prognosis of prostate carcinoma?

Kang

Ha²,

Kim³

et al. 2012

Asian J Androl

View full text Add to dashboard Cite

MicroRNAs (miRs) are small noncoding RNAs that have been reported to be promising diagnostic tools. We used quantitative real-time reverse transcription PCR (RT-qPCR) to analyze differentially expressed miRNAs in prostate tumor samples to determine its prognostic value. From 2007 to 2009, tumor tissues were obtained from 73 radical prostatectomy specimens. Differentially expressed miR-96, -145 and -221 were validated by TaqMan RT-qPCR using all 73 tissues. The prognostic value was assessed in terms of biochemical recurrence using Kaplan-Meier and Cox regression analyses. For our patient cohort, the mean age was 64.7 years (50-76 years) and the mean prostate-specific antigen (PSA) was 7.5 ng ml 21 . During the follow-up period (mean, 19.4 months), 14 of 73 (19.2%) patients developed biochemical recurrence. Expression of miR-96, -145 and -221 correlated strongly with each other, but there were no correlations between miRNA expression and clinicopathologic parameters. Kaplan-Meier survival curves using the log-rank test showed a decreased biochemical recurrence-free interval with pathologic stage (P,0.001). In addition, patients with Gleason scores over 8, compared with those with a Gleason score of 6, showed a decreased biochemical recurrence-free interval in Kaplan-Meier analysis (P50.001). However, expression of miR-96, -145 and -221 did not correlate with the biochemical recurrence interval in Kaplan-Meier survival curves or by multivariate analysis using the Cox proportional hazard regression model, either. In conclusion, we did not observe a significant correlation between the expression of miR-96, -145 and -221 and clinicopathologic parameters. To utilize miRNA as a diagnostic tool in clinical practice, more research is needed to understand miRNA mechanisms, identify miRNA targets, and further characterize miRNA function.

show abstract

“…Ma et al recently showed that hsamiR-10b was induced in response to the transcription factor TWIST. 18 TWIST is a HIF target gene 19 and is an adverse prognostic factor in both HNSCC 19 and esophageal SCC. 20 Tumor hypoxia interacts with other genetic abnormalities in the cell.…”

mentioning

confidence: 99%

hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer

Gee

Camps

Buffa

et al. 2010

Cancer

168

154

View full text Add to dashboard Cite

BACKGROUND:Hypoxia is an important mechanism of treatment resistance in head and neck squamous cell carcinoma (HNSCC). MicroRNAs are short noncoding RNAs that regulate multiple mRNAs and are frequently dysregulated in cancer. The authors have investigated the role of 3 microRNAs, including the hypoxia-induced hsa-miR-210, as potential markers of hypoxia or prognosis. METHODS: Three hypoxia-related microRNAs, hsa-miR-210, hsa-miR-21, and hsa-miR-10b, were measured in 46 samples from patients with HNSCC. Expression levels were correlated with clinicopathological variables and other markers of hypoxia: a published 99-gene hypoxia metagene, individual hypoxia-related genes such as TWIST1, and immunohistochemical expression of hypoxia-inducible factor 1 and its target gene carbonic anhydrase 9. We then performed survival analyses to investigate the prognostic significance of these microRNAs. RESULTS: Only the level of hsa-miR-210 was significantly correlated with other markers of hypoxia, including the 99-gene hypoxia metagene (rho ¼ 0.67, P < .001). We found no association between hsa-miR-210, hsamiR-21, or hsa-miR-10b and clinicopathological variables such as tumor size, differentiation, and stage. However, high levels of hsa-miR-210 were associated with locoregional disease recurrence (P ¼ .001) and short overall survival (P ¼ .008). hsa-miR-21 and hsa-miR-10b had no prognostic significance. CONCLUSIONS: Expression of hsa-miR-210 in head and neck cancer correlates with other approaches for assessing hypoxia and is associated with prognosis. This warrants further study as a classification marker of patients for therapies involving modulation of hypoxia.

show abstract

Tumour invasion and metastasis initiated by microRNA-10b in breast cancer

Cited by 2,328 publications

References 45 publications

microRNA-10b is a prognostic biomarker for melanoma

microRNA-10b is a prognostic biomarker for melanoma

Do microRNA 96, 145 and 221 expressions really aid in the prognosis of prostate carcinoma?

hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer

Contact Info

Product

Resources

About